Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02805894 · ClinicalTrials.gov registry record · Phase 1
NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate Adenocarcinoma
A Phase 1 study, sponsored by Nanobiotix.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT02805894 is a Phase 1 study that was terminated before completion, run by Nanobiotix. The registered enrollment target is 5 participants.
The verdict
NCT02805894, a Phase 1 study, was terminated before completion, sponsored by Nanobiotix.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This study is a Phase 1/2 open-label involving 2 groups of patients newly diagnosed with either unfavorable intermediate risk or high risk prostate adenocarcinoma. One group will receive only EBRT and the other group will receive a Brachytherapy boost and EBRT. Both groups will receive treatment with androgen deprivation. There will be 2 consecutive steps, a dose escalation and a subsequent dose expansion part.
Interventions
- DRUG NBTXR3 activated by IMRT only
- DRUG NBTXR3 activated by Brachytherapy & IMRT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2017-11-15 |
| Est. Completion | 2020-03-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02805894
The ClinicalTrials.gov registry entry for NCT02805894 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nanobiotix, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which NBTXR3 activated by IMRT only is the first listed.
NCT02805894 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02805894 about?
NCT02805894 is a clinical study titled "NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate Adenocarcinoma". This study is a Phase 1/2 open-label involving 2 groups of patients newly diagnosed with either unfavorable intermediate risk or high risk prostate adenocarcinoma. One group will receive only EBRT and the other group will receive a Brachytherapy boost and EBRT. Both groups will receive treatment wit...
What is the current status of trial NCT02805894?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2017-11-15. Estimated completion is 2020-03-19.
What interventions are being tested in trial NCT02805894?
The interventions under investigation include: NBTXR3 activated by IMRT only (DRUG), NBTXR3 activated by Brachytherapy & IMRT (DRUG).
Who is sponsoring clinical trial NCT02805894?
This trial is sponsored by Nanobiotix, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.